Concord Biotech

Market Cap: Small Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE338H01029
NSEID: CONCORDBIO
BSEID: 543960

INR

1,325.00

-54.15 (-3.93%)

BSENSE

Dec 17

BSE+NSE Vol: 65.62 k

{
  "main_header": {
    "sid": 10038977,
    "name": "Concord Biotech",
    "stock_name": "Concord Biotech",
    "full_name": "Concord Biotech Ltd",
    "name_url": "stocks-analysis/concord-biotech",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,325.00",
    "chg": -54.15,
    "chgp": "-3.93%",
    "dir": -1,
    "prev_price": "1,379.15",
    "mcapval": "14,343.00 Cr",
    "mcap": "Small Cap",
    "scripcode": 543960,
    "symbol": "CONCORDBIO",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE338H01029",
    "curr_date": "Dec 17",
    "curr_time": "",
    "bse_nse_vol": "65.62 k",
    "exc_status": "Active",
    "traded_date": "Dec 17, 2025",
    "traded_date_str": "2025 12 17",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/concord-biotech-10038977-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Concord Biotech Stock Falls to 52-Week Low of Rs.1325 Amidst Market Pressure",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/concord-biotech-stock-falls-to-52-week-low-of-rs-1325-3761494",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/ConcordBiotech_priceRelatedfactors_3761494.png",
        "date": "2025-12-17 15:55:04",
        "description": "Concord Biotech’s shares touched a fresh 52-week low of Rs.1325 today, marking a significant decline amid broader market fluctuations and sector underperformance. The stock’s intraday movement reflected a drop of 3.93%, underperforming the Pharmaceuticals & Biotechnology sector by nearly 4%."
      },
      {
        "title": "Concord Biotech Stock Falls to 52-Week Low of Rs.1325",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/concord-biotech-stock-falls-to-52-week-low-of-rs-1325-3761493",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/ConcordBiotech_priceRelatedfactors_3761493.png",
        "date": "2025-12-17 15:55:02",
        "description": "Concord Biotech’s shares reached a fresh 52-week low of Rs.1325 today, marking a significant decline amid broader market fluctuations and sectoral pressures. The stock underperformed its Pharmaceuticals & Biotechnology sector peers, reflecting ongoing concerns about its recent financial performance and valuation metrics."
      },
      {
        "title": "Concord Biotech Falls to 52-Week Low of Rs.1341.7 Amid Market Pressure",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/concord-biotech-stock-falls-to-52-week-low-of-rs13417-3753701",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/ConcordBiotech_priceRelatedfactors_3753701.png",
        "date": "2025-12-09 10:52:53",
        "description": "Concord Biotech's stock reached a fresh 52-week low of Rs.1341.7 today, marking a significant decline amid broader market fluctuations and sectoral pressures. The stock has recorded a consecutive two-day fall, reflecting a cumulative return of -3.96% over this period, underperforming its Pharmaceuticals & Biotechnology sector peers."
      },
      {
        "title": "Why is Concord Biotech falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-concord-biotech-fallingrising-3752545",
        "imagepath": "",
        "date": "2025-12-09 01:23:02",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Movement and Market Context</strong></p>\n<p>Concord Biotech’s share price hit a fresh 52-week low of ₹1,352.30 during intraday trading on 08-Dec, marking a 3.69% decline from previous levels. The stock underperformed its sector by 1.81% on the day, with a weighted average price indicating that most trading volume occurred near the day’s low. This suggests selling pressure dominated throughout the session. Furthermore, the stock is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a bearish trend and weak technical momentum.</p>\n<p>Investor participation has also waned, with delivery volumes on 05-Dec falling by 27.32% compared to the five-day average. Although liquidity remains adequate for moderate trade sizes,..."
      },
      {
        "title": "Concord Biotech Stock Falls to 52-Week Low of Rs 1364",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/concord-biotech-stock-falls-to-52-week-low-of-rs1364-3751534",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/ConcordBiotech_priceRelatedfactors_3751534.png",
        "date": "2025-12-08 12:54:11",
        "description": "Concord Biotech’s share price reached a fresh 52-week low of Rs 1364 today, marking a significant decline amid broader market fluctuations and sectoral pressures. The stock’s performance contrasts with the broader Sensex, which remains close to its 52-week high, highlighting the challenges faced by the pharmaceutical and biotechnology company over the past year."
      },
      {
        "title": "Concord Biotech Stock Falls to 52-Week Low of Rs 1364",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/concord-biotech-falls-to-52-week-low-of-rs-1364-amidst-continued-underperformance-3751530",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/ConcordBiotech_priceRelatedfactors_3751530.png",
        "date": "2025-12-08 12:54:01",
        "description": "Concord Biotech’s shares reached a new 52-week low of Rs 1364 today, marking a significant decline amid broader market fluctuations and sectoral pressures. The stock’s performance contrasts with the Sensex, which remains close to its 52-week high, highlighting challenges specific to the company within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Concord Biotech’s Evaluation Revised Amidst Challenging Financial and Market Trends",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/concord-biotech-downgraded-to-strong-sell-amid-weak-financial-and-technical-indicators-3733005",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/ConcordBiotech_mojoScore_3733005.png",
        "date": "2025-11-27 10:06:45",
        "description": "Concord Biotech, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting recent financial results and market performance. The company’s assessment metrics have shifted downward, influenced by a combination of valuation concerns, financial trends, and technical indicators."
      },
      {
        "title": "Concord Biotech Q2 FY26: Sharp Profit Decline Amid Revenue Volatility Raises Red Flags",
        "link": "https://www.marketsmojo.com/news/result-analysis/concord-biotech-q2-fy26-sharp-profit-decline-amid-revenue-volatility-raises-red-flags-3718506",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/ConcordBiotech_quaterlyResult_3718506.png",
        "date": "2025-11-15 11:01:09",
        "description": "Concord Biotech Limited, the Ahmedabad-based pharmaceutical and biotechnology company with a market capitalisation of ₹15,244 crores, reported a consolidated net profit of ₹63.58 crores for Q2 FY26, representing a sharp decline of 33.59% year-on-year from ₹95.74 crores in Q2 FY25. The quarter-on-quarter performance showed a recovery of 44.30% from Q1 FY26's ₹44.06 crores, though this improvement fails to mask deeper concerns about the company's earnings trajectory. The stock has responded negatively to the company's recent performance, declining 20.80% over the past year and underperforming the broader pharmaceuticals sector by 24.56 percentage points."
      },
      {
        "title": "How has been the historical performance of Concord Biotech?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-concord-biotech-3699794",
        "imagepath": "",
        "date": "2025-11-13 23:50:41",
        "description": "Answer:\nThe historical performance of Concord Biotech shows a consistent growth trajectory in key financial metrics over the past four years.\n\nBreakdown:\nConcord Biotech's net sales have increased from 712.93 Cr in Mar'22 to 1,200.09 Cr in Mar'25, reflecting a strong upward trend. Total operating income followed a similar pattern, rising from 712.93 Cr to 1,200.09 Cr during the same period. The company's total expenditure, excluding depreciation, also grew from 439.66 Cr in Mar'22 to 693.76 Cr in Mar'25, indicating increased operational costs. Operating profit (PBDIT) saw a significant rise from 296.69 Cr in Mar'22 to 550.78 Cr in Mar'25, showcasing improved profitability. Profit before tax increased from 241.16 Cr to 495.87 Cr, while profit after tax rose from 178.57 Cr to 372.96 Cr, demonstrating effective cost management and revenue generation. The earnings per share (EPS) improved from 16.72 in Mar'22 t..."
      }
    ],
    "total": 334,
    "sid": "10038977",
    "stock_news_url": "https://www.marketsmojo.com/news/concord-biotech-10038977"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Cessation",
      "datetime": "08-Dec-2025",
      "details": "Early Retirement of Chief Financial officer (KMP) w.e.f. closing of working business hours on January 052026",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Change in Management",
      "datetime": "08-Dec-2025",
      "details": "Early retirement of Chief Financial Officer",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
      "datetime": "19-Nov-2025",
      "details": "Transcript of Q2FY26 earning call held on November 14 2025",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Concord Biotech Ltd has declared <strong>1070%</strong> dividend, ex-date: 03 Sep 25",
          "dt": "2025-09-03",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Concord Biotech Stock Falls to 52-Week Low of Rs.1325 Amidst Market Pressure

2025-12-17 15:55:04

Concord Biotech’s shares touched a fresh 52-week low of Rs.1325 today, marking a significant decline amid broader market fluctuations and sector underperformance. The stock’s intraday movement reflected a drop of 3.93%, underperforming the Pharmaceuticals & Biotechnology sector by nearly 4%.

Concord Biotech Stock Falls to 52-Week Low of Rs.1325

2025-12-17 15:55:02

Concord Biotech’s shares reached a fresh 52-week low of Rs.1325 today, marking a significant decline amid broader market fluctuations and sectoral pressures. The stock underperformed its Pharmaceuticals & Biotechnology sector peers, reflecting ongoing concerns about its recent financial performance and valuation metrics.

Concord Biotech Falls to 52-Week Low of Rs.1341.7 Amid Market Pressure

2025-12-09 10:52:53

Concord Biotech's stock reached a fresh 52-week low of Rs.1341.7 today, marking a significant decline amid broader market fluctuations and sectoral pressures. The stock has recorded a consecutive two-day fall, reflecting a cumulative return of -3.96% over this period, underperforming its Pharmaceuticals & Biotechnology sector peers.

Why is Concord Biotech falling/rising?

2025-12-09 01:23:02

Recent Price Movement and Market Context

Concord Biotech’s share price hit a fresh 52-week low of ₹1,352.30 during intraday trading on 08-Dec, marking a 3.69% decline from previous levels. The stock underperformed its sector by 1.81% on the day, with a weighted average price indicating that most trading volume occurred near the day’s low. This suggests selling pressure dominated throughout the session. Furthermore, the stock is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a bearish trend and weak technical momentum.

Investor participation has also waned, with delivery volumes on 05-Dec falling by 27.32% compared to the five-day average. Although liquidity remains adequate for moderate trade sizes,...

Concord Biotech Stock Falls to 52-Week Low of Rs 1364

2025-12-08 12:54:11

Concord Biotech’s share price reached a fresh 52-week low of Rs 1364 today, marking a significant decline amid broader market fluctuations and sectoral pressures. The stock’s performance contrasts with the broader Sensex, which remains close to its 52-week high, highlighting the challenges faced by the pharmaceutical and biotechnology company over the past year.

Concord Biotech Stock Falls to 52-Week Low of Rs 1364

2025-12-08 12:54:01

Concord Biotech’s shares reached a new 52-week low of Rs 1364 today, marking a significant decline amid broader market fluctuations and sectoral pressures. The stock’s performance contrasts with the Sensex, which remains close to its 52-week high, highlighting challenges specific to the company within the Pharmaceuticals & Biotechnology sector.

Concord Biotech’s Evaluation Revised Amidst Challenging Financial and Market Trends

2025-11-27 10:06:45

Concord Biotech, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting recent financial results and market performance. The company’s assessment metrics have shifted downward, influenced by a combination of valuation concerns, financial trends, and technical indicators.

Concord Biotech Q2 FY26: Sharp Profit Decline Amid Revenue Volatility Raises Red Flags

2025-11-15 11:01:09

Concord Biotech Limited, the Ahmedabad-based pharmaceutical and biotechnology company with a market capitalisation of ₹15,244 crores, reported a consolidated net profit of ₹63.58 crores for Q2 FY26, representing a sharp decline of 33.59% year-on-year from ₹95.74 crores in Q2 FY25. The quarter-on-quarter performance showed a recovery of 44.30% from Q1 FY26's ₹44.06 crores, though this improvement fails to mask deeper concerns about the company's earnings trajectory. The stock has responded negatively to the company's recent performance, declining 20.80% over the past year and underperforming the broader pharmaceuticals sector by 24.56 percentage points.

How has been the historical performance of Concord Biotech?

2025-11-13 23:50:41

Answer: The historical performance of Concord Biotech shows a consistent growth trajectory in key financial metrics over the past four years. Breakdown: Concord Biotech's net sales have increased from 712.93 Cr in Mar'22 to 1,200.09 Cr in Mar'25, reflecting a strong upward trend. Total operating income followed a similar pattern, rising from 712.93 Cr to 1,200.09 Cr during the same period. The company's total expenditure, excluding depreciation, also grew from 439.66 Cr in Mar'22 to 693.76 Cr in Mar'25, indicating increased operational costs. Operating profit (PBDIT) saw a significant rise from 296.69 Cr in Mar'22 to 550.78 Cr in Mar'25, showcasing improved profitability. Profit before tax increased from 241.16 Cr to 495.87 Cr, while profit after tax rose from 178.57 Cr to 372.96 Cr, demonstrating effective cost management and revenue generation. The earnings per share (EPS) improved from 16.72 in Mar'22 t...

View All News